NDC and Billing Codes for KEYTRUDA
Melanoma: Advanced and Adjuvant Settings
NSCLC: Advanced, Adjuvant, and Neoadjuvant and Adjuvant Settings
Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma
Metastatic or Unresectable, Recurrent HNSCC
Relapsed or Refractory Classical Hodgkin Lymphoma
Refractory or Relapsed PMBCL
Advanced Urothelial Cancer
High-Risk Non-Muscle Invasive Bladder Cancer
Advanced MSI-H/dMMR Cancers
Advanced MSI-H/dMMR CRC
Advanced HER2-Negative Gastric or GEJ Adenocarcinoma
Advanced Esophageal or GEJ Carcinoma
Advanced Cervical Cancer
Hepatocellular Carcinoma
Advanced Biliary Tract Cancer
Advanced Merkel Cell Carcinoma
RCC: Advanced and Adjuvant Settings
Endometrial Carcinoma
Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced cSCC
High-Risk Early-Stage TNBC and Advanced TNBC
Selected Safety Information for KEYTRUDA® (pembrolizumab)